SCHEMBL2230797

SCHEMBL2230797

Cc1ccc(-c2nc3ccc(C)cn3c2Cn2cnc3ccccc32)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 5/20 0.60
CYP11B1 P15538 5/20 0.54
CYP11B2 P19099 5/20 0.54
LMNA P02545 3/20 0.54
SMN1; SMN2 Q16637 2/20 0.54
HTT P42858 2/20 0.54
SLC2A1 P11166 2/20 0.48
KDM4E B2RXH2 2/20 0.48
ALB P02768 1/20 0.48
CYP3A4 P08684 1/20 0.48
CHRM1 P11229 1/20 0.48
GABRA1 P14867 1/20 0.48
HPGD P15428 1/20 0.48
GABRB1 P18505 1/20 0.48
GABRG2 P18507 1/20 0.48
GABRB3 P28472 1/20 0.48
GABRA3 P34903 1/20 0.48
ADRA1A P35348 1/20 0.48
OPRK1 P41145 1/20 0.48
HTR2B P41595 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2225712 0.84 SMN1; SMN2 (0.47) PKMLMNASMN1; SMN2HTTSLC2A1
SCHEMBL2222880 0.81 SMN1; SMN2 (0.57) LMNASMN1; SMN2HTTSLC2A1KDM4E
SCHEMBL2230114 0.81 SMN1; SMN2 (0.52) PKMLMNASMN1; SMN2HTTSLC2A1
SCHEMBL2224430 0.79 GABRA1 (0.50) LMNASMN1; SMN2HTTSLC2A1KDM4E
SCHEMBL2226053 0.78 SMN1; SMN2 (0.57) LMNASMN1; SMN2HTTSLC2A1KDM4E
SCHEMBL2275461 0.77 SMN1; SMN2 (0.56) LMNASMN1; SMN2HTTSLC2A1KDM4E
SCHEMBL2223787 0.76 GABRA1 (0.52) LMNASMN1; SMN2HTTSLC2A1KDM4E
SCHEMBL20908773 0.75 PKM (1.00) PKMCYP11B1CYP11B2LMNASMN1; SMN2
SCHEMBL2273490 0.75 GABRA1 (0.51) LMNASMN1; SMN2HTTSLC2A1KDM4E
SCHEMBL1430418 0.75 SMN1; SMN2 (0.48) LMNASMN1; SMN2HTTSLC2A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130289013-A1 IMIDAZO[1,2-a]PYRIDINE COMPOUNDS SUNOVION PHARMACEUTICALS INC. 2013-10-31 US disclosed
US-8497278-B2 Imidazo[1,2-a]pyridine compounds SUNOVION PHARMACEUTICALS INC. (US) 2013-07-30 US disclosed
US-20110166146-A1 IMIDAZO[1,2-a]PYRIDINE COMPOUNDS SUNOVION PHARMACEUTICALS INC. (US) 2011-07-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110166146-A1 IMIDAZO[1,2-a]PYRIDINE COMPOUNDS PAICS, ITPA, DPYD PKM 1649/4885CYP11B1 83/4885CYP11B2 35/4885
US-20130289013-A1 IMIDAZO[1,2-a]PYRIDINE COMPOUNDS PAICS, ITPA, DPYD PKM 1649/4885CYP11B1 83/4885CYP11B2 35/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.